Hospital laboratory routine molecular infectious-disease testing
Molecular assays (respiratory, GI, bloodstream, meningitis panels and single-target PCR) run in hospital and clinical laboratories to support routine inpatient and outpatient diagn
Intelligence / Healthtech & medtech market map / Diagnostics and laboratory products / Molecular and specialised diagnostics
Molecular assays, sequencing-based products and specialty diagnostic systems for targeted disease, oncology and inherited-condition testing, including associated reagents and consumables.
Split by customer type.
Molecular assays (respiratory, GI, bloodstream, meningitis panels and single-target PCR) run in hospital and clinical laboratories to support routine inpatient and outpatient diagn
Sequencing-based and array/PCR-plus-molecular specialty products used to diagnose inherited and rare conditions and to profile tumour genomics for targeted therapy selection, inclu
Molecular and sequencing-based products, reagents, reference materials and services bought by biotechnology and pharmaceutical companies to develop and validate assays, qualify bio
Compact, cartridge-based molecular systems used at the point of care or near the bedside (emergency departments, urgent care, intensive care, outpatient clinics) to return a syndro
$14.8B ($11.0B–$20.0B) · 2025 · Bottom-up
Bottom-up: molecular diagnostics estimated at ~12% of the USD 118.6bn global diagnostic tests market (2025) [3][4], giving ~USD 14.2bn, plus specialty/oncology and inherited-condition systems not captured in that base, rounded to USD 14.8bn. Cross-check: North America, at 40.0% of clinical diagnostics value [1], is the fastest adopter of molecular panels [1]; Roche Diagnostics grew 2% at constant exchange rates in 2025 [3][4]. Forecast scaled at the 6.60% CAGR [3][4] to ~USD 26bn by 2032. Low confidence: no source publishes a standalone molecular diagnostics revenue pool.
// Sell into Molecular and specialised diagnostics